sign in · help · news · about ·

BibSonomy :: user :: kanefendt ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

>
|
<

bookmarks

bookmarks per page: 5 10 20 50 100

RSS BibTeX RDF more

publications

(6)

<< < 1 > >>

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
J. M. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Proc.Natl.Acad.Sci.U.S.A 104(43):17069-17074 (2007)
to & A Administration Agents Angiogenesis Animals Antineoplastic Antitumor Assays Blood Cell Dose-Response Drug Endothelial Factor Female Growth Humans Hypoxia Indoles Inducing Line Mice Model Neoplasms Organ Outcome Placenta Pregnancy Proteins Pyrroles RANGE Receptor-2 Relationship Research Schedule Scid Specificity Treatment Tumor Tyrosine Vascular Xenograft administration blood dosage drug effects metabolism pathology pharmacology protein response therapy toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
H. M. Verheul, and H. M. Pinedo Nat.Rev.Cancer 7(6):475-485 (2007)
to & A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. Deprimo, C. M. Baum, and K. D. Miller J Clin Oncol 26(11):1810-1816 (2008)
to & Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors
F. A. Eskens, N. Steeghs, J. Verweij, J. L. Bloem, O. Christensen, Doorn L. van, J. Ouwerkerk, M. J. Jonge, J. W. Nortier, J. Kraetzschmar, P. Rajagopalan, and H. Gelderblom J.Clin.Oncol. 27(25):4169-4176 (2009)
to & A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Antiangiogenesis research is booming, as questions and studies proliferate
V. Brower J.Natl.Cancer Inst. 101(11):780-781 (2009)
to & Administration Analysis Angiogenesis Antibodies Antineoplastic Biological Chemotherapy Colorectal Combined Controlled Drug Humans Inhibitors Markers Monoclonal Neoplasms Pericytes Protocols Randomized Research Schedule Survival Topic Trials Tumor administration analysis as blood dosage drug effects mortality supply therapeutic therapy use by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)
Increased plasma vascular endothelial growth factor VEGF as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G. Bocci, S. Man, S. K. Green, G. Francia, J. M. Ebos, J. M. Du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, A. Davidoff, J. Huber, D. J. Hicklin, and R. S. Kerbel Cancer Res. 64(18):6616-6625 (2004)
to & A Adenocarcinoma Administration Angiogenesis Animals Antibodies Antineoplastic Biological Blood Cell Chemotherapy Colorectal Combined Drug Endothelial Factor Growth Human Humans Inhibitors Line Male Markers Messenger Mice Modality Monoclonal Neoplasms Neovascularization Nude Pathologic Platelets Prostatic Protocols RNA Receptor-2 Research Schedule Scid Therapy Tumor Vascular administration biosynthesis blood dosage genetics immunology metabolism protein supply therapy by kanefendt on Feb 5, 2010, 11:28 AM
URL | BibTeX (0)

<< < 1 > >>publications per page: 5 10 20 50 100

a gripper